Taylor L. Wilson

Taylor L. Wilson

Auto-generated profile, based on publicly available information

Taylor L. Wilson

Washington University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2021 in Cell Host & Microbe
Verified
Journal Article
Open access
CLChun-Yang Lin
Chun-Yang Lin
JWJoshua Wolf
Joshua Wolf
DBDavid C. Brice
David C. Brice
YSYilun Sun
Yilun Sun
MLMacauley Locke
Macauley Locke
MMMaureen A. McGargill
Maureen A. McGargill
SARS-CoV-2 infection causes diverse outcomes ranging from asymptomatic infection to respiratory distress and death. A major unresolved question is whether prior immunity to endemic, human common cold coronaviruses (hCCCoVs) impacts susceptibility to SARS-CoV-2 infection or immunity following infection and vaccination. Therefore, we analyzed samples from the same individuals before and after SARS-CoV-2 infection or vaccination. We found hCCCoV antibody levels increase after SARS-CoV-2 exposure, demonstrating cross-reactivity. However, a case-control study indicates that baseline hCCCoV antibody levels are not associated with protection against SARS-CoV-2 infection. Rather, higher magnitudes of pre-existing betacoronavirus antibodies correlate with more SARS-CoV-2 antibodies following infection, an indicator of greater disease severity. Additionally, immunization with hCCCoV spike proteins before SARS-CoV-2 immunization impedes the generation of SARS-CoV-2-neutralizing antibodies in mice. Together, these data suggest that pre-existing hCCCoV antibodies hinder SARS-CoV-2 antibody-based immunity following infection and provide insight on how pre-existing coronavirus immunity impacts SARS-CoV-2 infection, which is critical considering emerging variants.

6 July 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
TWTaylor L. Wilson
Taylor L. Wilson
HKHyunjin Kim
Hyunjin Kim
CCChing-Heng Chou
Ching-Heng Chou
DLDeanna Langfitt
Deanna Langfitt
RMRobert C. Mettelman
Robert C. Mettelman
PTPaul G Thomas
Paul G Thomas
Current chimeric antigen receptor-modified (CAR) T-cell products are evaluated in bulk, without assessing functional heterogeneity. We therefore generated a comprehensive single-cell gene expression and T-cell receptor (TCR) sequencing data set using pre- and postinfusion CD19-CAR T cells from blood and bone marrow samples of pediatric patients with B-cell acute lymphoblastic leukemia. We identified cytotoxic postinfusion cells with identical TCRs to a subset of preinfusion CAR T cells. These effector precursor cells exhibited a unique transcriptional profile compared with other preinfusion cells, corresponding to an unexpected surface phenotype (TIGIT+, CD62Llo, CD27−). Upon stimulation, these cells showed functional superiority and decreased expression of the exhaustion-associated transcription factor TOX. Collectively, these results demonstrate diverse effector potentials within preinfusion CAR T-cell products, which can be exploited for therapeutic applications. Furthermore, we provide an integrative experimental and analytic framework for elucidating the mechanisms underlying effector development in CAR T-cell products. Significance: Utilizing clonal trajectories to define transcriptional potential, we find a unique signature of CAR T-cell effector precursors present in preinfusion cell products. Functional assessment of cells with this signature indicated early effector potential and resistance to exhaustion, consistent with postinfusion cellular patterns observed in patients. This article is highlighted in the In This Issue feature, p. 2007

9 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
EGElizabeth A. R. Garfinkle
Elizabeth A. R. Garfinkle
PNPratima Nallagatla
Pratima Nallagatla
BSBinay Sahoo
Binay Sahoo
JDJinjun Dang
Jinjun Dang
MBMohammad Balood
Mohammad Balood
TGTanja A. Gruber
Tanja A. Gruber
CBFA2T3-GLIS2 is a fusion oncogene found in pediatric acute megakaryoblastic leukemia that is associated with a poor prognosis. We establish a model of CBFA2T3-GLIS2 driven acute megakaryoblastic leukemia that allows the distinction of fusion specific changes from those that reflect the megakaryoblast lineage of this leukemia. Using this model, we map fusion genome wide binding that in turn imparts the characteristic transcriptional signature. A network of transcription factor genes bound and upregulated by the fusion are found to have downstream effects that result in dysregulated signaling of developmental pathways including NOTCH, Hedgehog, TGFβ, and WNT. Transcriptional regulation is mediated by homo-dimerization and binding of the ETO transcription factor through the nervy homology region 2. Loss of nerve homology region 2 abrogated the development of leukemia, leading to downregulation of JAK/STAT, Hedgehog, and NOTCH transcriptional signatures. These data contribute to the understanding of CBFA2T3-GLIS2 mediated leukemogenesis and identify potential therapeutic vulnerabilities for future studies.

4 April 2023
Verified
Other
Open access
TWTaylor L. Wilson
Taylor L. Wilson
HKHyunjin Kim
Hyunjin Kim
CCChing-Heng Chou
Ching-Heng Chou
DLDeanna Langfitt
Deanna Langfitt
RMRobert C. Mettelman
Robert C. Mettelman
PTPaul G Thomas
Paul G Thomas
Current chimeric antigen receptor-modified (CAR) T-cell products are evaluated in bulk, without assessing functional heterogeneity. We therefore generated a comprehensive single-cell gene expression and T-cell receptor (TCR) sequencing data set using pre- and postinfusion CD19-CAR T cells from blood and bone marrow samples of pediatric patients with B-cell acute lymphoblastic leukemia. We identified cytotoxic postinfusion cells with identical TCRs to a subset of preinfusion CAR T cells. These effector precursor cells exhibited a unique transcriptional profile compared with other preinfusion cells, corresponding to an unexpected surface phenotype (TIGIT+, CD62Llo, CD27−). Upon stimulation, these cells showed functional superiority and decreased expression of the exhaustion-associated transcription factor TOX. Collectively, these results demonstrate diverse effector potentials within preinfusion CAR T-cell products, which can be exploited for therapeutic applications. Furthermore, we provide an integrative experimental and analytic framework for elucidating the mechanisms underlying effector development in CAR T-cell products.Significance:Utilizing clonal trajectories to define transcriptional potential, we find a unique signature of CAR T-cell effector precursors present in preinfusion cell products. Functional assessment of cells with this signature indicated early effector potential and resistance to exhaustion, consistent with postinfusion cellular patterns observed in patients.This article is highlighted in the In This Issue feature, p. 2007

4 April 2023
Verified
Other
Open access
TWTaylor L. Wilson
Taylor L. Wilson
HKHyunjin Kim
Hyunjin Kim
CCChing-Heng Chou
Ching-Heng Chou
DLDeanna Langfitt
Deanna Langfitt
RMRobert C. Mettelman
Robert C. Mettelman
PTPaul G Thomas
Paul G Thomas
Supplementary Figure from Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages

4 April 2023
Verified
Other
Open access
TWTaylor L. Wilson
Taylor L. Wilson
HKHyunjin Kim
Hyunjin Kim
CCChing-Heng Chou
Ching-Heng Chou
DLDeanna Langfitt
Deanna Langfitt
RMRobert C. Mettelman
Robert C. Mettelman
PTPaul G Thomas
Paul G Thomas
Supplementary Data from Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages